Multiprobe fluorescence in situ hybridisation: Prognostic perspectives in superficial bladder cancer

Journal of Clinical Pathology

Volumn 59, Issue 9, 2006, Pages 984-987

  Mian, C ^a   Lodde, M ^a   Comploj, E ^a   Lusuardi, L ^a   Palermo, S ^a   Mian, M ^a   Maier, K ^a   Pycha, A ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; UNIVARIATE ANALYSIS; URINALYSIS; URINE CYTOLOGY; UROGENITAL TRACT CANCER;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; GENES, P16; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 33748879225     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.035394     Document Type: Article

References (32)

1. Chopin DK, Gattengo B. Superficial bladder tumors. Eur Urol 2002;42:533-41.
2. Soloway MS. Managing superficial bladder cancer: an overview. Urology 1992;40:5-10.
3. Spruck CH III, Ohneseit PF, Gonzales-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
4. Lutzeyer W, Rübben H, Dahm H. Prognostic parameters in superficial bladder cancer. An analysis of of 315 cases. J Urol 1982;127:250-2.
5. Heney NM, Ahmed S, Flanadan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:142-7.
6. Krüger S, Mahnken A, Kausch I, et al. P16 immunoreactivity is an independant predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 2005;47:463-7.
7. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma. Feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-8.
8. Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991;146:28-31.
9. Bol MGW, Baak JPA, Buhr-Wildhagen S, et al. Reproductability and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of bladder cancer. J Urol 2003;169:1291-4.
10. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4A) in cancer progression. Exp Cell Res 2001;264:42-55.
11. Williamsson MP, Elder PA, Shaw ME, et al. P16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995;4:1569-77.
12. Reznikoff CA, Sarkar S, Juelicher P, et al. Genetical alterations and biological pathways in human bladder cancer. Urol Oncol 2000;5:191-203.
13. Hitchings AW, Kumar M, Jordan S, et al. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRB. Br J Cancer 2004;91:552-7.
14. Shariat SF, Tokunaga H, Zhou J, et al. P53, p21, pRB and pi 6 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-24.
15. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, cyclinD1 and cyclinD3) and proliferation index (ki67-Mib1). Eur Urol 2004;45:606-12.
16. Mhawech P, Greloz V, Oppikofer C, et al. Expression of cell cycle proteins in T1a and T1b urothelial blader carcinoma and and their value in predicting tumor progression. Cancer 2004;100:2367-75.
17. Sobin LH, Wittekind Ch. UICC TNM classification of malignant tumours, 6th edn. New York: Wiley-Liss, 2002:199.
18. Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79-86.
19. Pycha A, Lodde M, Comploj E, et al. Intermediate risk urothelial carcinoma: an unresolved problem? Urology 2004;63:472-5.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Bryan RT, Wallace DMA. Superficial bladder cancer - time to uncouple pT1 tumours from pTa tumours. BJU Int 2002;90:846-52.
22. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
23. Esrig D, Spruck Ch III, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
24. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21 WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
25. Pycha A, Mian C, Haitel A, et al. Fluorescence in situ hybridization detects more aggressive types of primarily non invasive (pTa) bladder cancer. J Urol 1997;157:2116-9.
26. Pycha A, Mian C, Posch B, et al. Numerical chromosomal aberrations in muscle invasive squamous and transitional cell cancer of the urinary bladder: an alternative to classic prognostic factors? Urology 1999;53:1005-10.
27. Gallucci M, Guadagnini F, Marzano R, et al. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9 and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol 2005;58:367-71.
28. Bollmann M, Heller H, Bankfalvi A, et al. Quantitative molecular urinary cytology by fluorescence in situ hybridisation: a tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005;95:1219-25.
29. Mazzucchelli R, Barbisan F, Stramazzotti D, et al. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma. A fluorescence in situ hybridization study and correlation with histologic features. Anal Quant Cytol Histol 2005;27:143-51.
30. Raitanen MP, Tammela TL, Kallioniemi M, et al. P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997;157:1250-3.
31. Bernardini S, Billerey C, Martin M, et al. The predictive value of muscularis mucosae invasion and p53 overexpression on progression of stage T1 bladder carcinoma. J Urol 2001;165:42-6.
32. Waldman FM, Caroll PR, Kerschmann R, et al. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res 1991;51:3807.